N/A N=41,054 Pediatric Blood Pressure Clinical Decision Support Tool (PedsBP CDS)
Hypertension
Primary: Blood Pressure Remeasurement — 245; 829; 1813 participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=35 Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
Hypertension
Primary: Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP). — -2.86 Millimeters of Mercury (mm Hg)
Phase 3 N=27 A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension
Pediatric Hypertension
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 19; 5 Participants
Phase 4 N=5 Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9
N/A N=35 Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension
Essential Hypertension
Primary: The Number of Patients for Whom Each Drug is Selected as the Preferred Therapy — 16; 8; 4 Participants
Phase 3 N=215 An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension
Hypertension
Primary: Change in Seated Diastolic Blood Pressure Between AZM and Placebo — 3.9; -1.6 mmHg
Phase 4 N=49 N-of-1 Trials In Children With Hypertension
Pediatric Hypertension
Primary: Number of Participants With Ambulatory Blood Pressure (BP) Control at 6 Months — 8; 8; 10; 15 Participants
Phase 1 N=24 Olmesartan Pediatric Pharmacokinetic (PK) Study
Hypertension
Primary: For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t) — 7874; 5851 ng/mL*hr
N/A N=31,579 Electronic Health Record-Based Clinical Decision Support to Improve Blood Pressure Management in Adolescents
Hypertension · Pre Hypertension · Obesity
Primary: Participants With Clinical Recognition of Hypertension — 160; 51 Participants — p=<.001
Phase 3 N=101 Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)
Hypertension
Primary: Mean Change From Baseline in Systolic Blood Pressure — -7.31; -7.65; -6.67 mmHg — p=0.753
Phase 3 N=267 Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Endpoint (Phase 1) — -5.54; -5.42; -9.03 millimeter(s) of mercury (mmHg)
N/A N=9 Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease
Hypertension · Chronic Kidney Diseases
Primary: Change in 24-hour Mean Arterial Pressure (MAP) — 1.4 mmHg
Phase 3 N=33 Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients
Hypertension Secondary to Kidney Transplant
Primary: Number of Participants Who Are Non Dippers — 7; 12 Participants
Phase 3 N=74 Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure
Hypertension
Primary: Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6) — -8.3; -10.3; -14.4 mm Hg — p=0.0990
Phase 3 N=300 Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — -15.4; -14.1 mm Hg
N/A N=64 Youth-Led Intervention to Improve Blood Pressure
Hypertension · Adolescent Behavior · Health Knowledge, Attitudes, Practice
Primary: School Cohort: Hypertension Knowledge (Youth and Adult) — 17.5; 17.6; 17.9; 17.8 number of questions correct out of 21
Phase 3 N=261 Obese Hypertension Study (0954-315)
Hypertension
Primary: Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 — -12.1; -6.8 mm Hg
Phase 3 N=208 An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at to End of Study — -7.63; -7.94 millimeter(s) of mercury (mmHg) — p=0.0040
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
Phase 2 N=51 Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma
Hypertension · Osteonecrosis · Osteonecrosis Due to Drug
Primary: Extensive Radiographic Osteonecrosis — 20; 21; 1; 2 Participants — p=0.7139
Phase 4 N=6 Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension · Hypertension, Pulmonary
Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2
N/A N=206 Remote Surveillance of Postpartum Hypertension
Hypertension in Pregnancy
Primary: Number of Participants Whose Blood Pressure Was Assessed in the First Ten Days Following Discharge — 45; 95 Participants
Phase 3 N=66 A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — 114.7; -11.2 millimeters of mercury (mmHg)
Phase 3 N=6 A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension
Pediatric Hypertension
Primary: AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to Time 24 Hours of TAK-536 (Azilsartan) — 6350.3; 6871.7 ng*hr/mL
Phase 3 N=127 Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
Pediatric Hypertension With or Without CKD
Primary: Change From Baseline in Mean Systolic Blood Pressure (MSBP) at Week 6 Endpoint — -1.2; -9.2; -6.9; -7.8 mmHg — p=0.0096
Phase 2 N=39 A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age
Hypertension
Primary: Maximum Plasma Concentration (Cmax) at Day 1 and Day 8 in 6-11 and 12-17 Year Old Patients — 76.8; 393.3; 82.2; 397.1 ng/ml
N/A N=5 A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure
Hypertension
Primary: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) — 0 Participants
N/A N=595 Implementing Hypertension Screening Guidelines in Primary Care
Hypertension,Essential · White Coat Hypertension
Primary: Percentage of Patient Visits With Completion of Out-of-office BP Monitoring Within 6 Months of an Eligible Visit During the Pre-Implementation Period — 0.6; 5.4…
Phase 3 N=93 Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
Hypertension
Primary: Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP) — -6.0; -8.9; -12.0 mm Hg
N/A N=202 Pregnancy-Related Hypertension: Adherence to a New Type of Monitoring
Gestational Hypertension · Preeclampsia · Chronic Hypertension With Pre-Eclampsia Complicating Childbirth
Primary: Adherence to the American College of Obstetricians and Gynecologists Guideline of Postpartum Blood Pressure Check Within 10 Days Postpartum — 59; 89 Participants…